Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.02 am

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA 00152 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 31/March/2019, 8.50 am
March 31, 2019
Intracardiac injection of Erythropoietin/Hematopoietin attenuates pathogenesis-associated with Myocardial infarction: Erythropoietin/Hematopoietin decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leukocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival, via up regulation of its target gene, 31/March/2019, 9.29 am
March 31, 2019
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promotes functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene

price-300[easy_payment currency=”USD”]


From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study provides, for the first time, mechanistic insight into how  Cyclic Helix-B peptide (CHBP), derived from erythropoietin/hematopoietin, protects against myocardial infarction.  

Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP), by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1)Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate aging; and (6) extend lifespan (fig 1). 

Figure 1. Cyclic Helix-B peptide (CHBP)-based therapy functions as a Cardioprotective agent. Mechanistic insights into how  Cyclin Helix-B peptide (CHBP)-based therapy induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival

Figure 2.  Cyclin Helix-B peptide (CHBP)  functions as a cardioprotective agent through induction of PNUTS

Thus, by injecting Cyclic Helix-B peptide (CHBP) into the myocardium of aged cardiac patients, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests, for the first time, that CHBP-based therapy may be used to protect against myocardial infarction or improve cardiac function after myocardial infarction (fig. 2).  


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does CHBP-based therapy increase the expression of PNUTS/Telomerase?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,   Intracardiac/epicardial injection of Cyclic Helix-B peptide (CHBP) protects against and promoter functional recovery after Myocardial Infarction:  CHBP, derived from erythropoietin/hematopoietin, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 31/March/2019, 9.03 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.